Please login to the form below
T-DM1
This page shows the latest T-DM1 news and features for those working in and with pharma, biotech and healthcare.
Immunotherapy and future directions in oncology
Those dendritic cells can activate cytotoxic T-cells which, after replicating, track and eradicate cancer cells. ... Kadcyla (trastuzumab emtansine, Genentech of Roche) targets HER2 receptors present in breast cancer and delivers an anti-microtubule
Latest news
-
EU backs Roche’s Kadcyla in breast cancer
Expectations are high for the Kadcyla, which is an antibody-drug conjugate (ADC) that combines the monoclonal antibody in Herceptin with ImmunoGen's DM1, a cytotoxic payload designed to boost its
-
Roche's Herceptin follow-up cleared in US
FDA approval for Kadcyla (formerly T-DM1) in breast cancer. Roche won approval in the US late last week for Kadcyla, its much-anticipated follow-up to breast cancer blockbuster Herceptin. ... The FDA has given the go-ahead to Kadcyla, formerly known as
-
Product updates from Japan
pylori", according to the partners. Chugai Pharmaceutical has filed for approval of trastuzumab emtansine (T-DM1) - originally developed by Roche/Genentech as a follow-up to their Herceptin (trastuzumab) blockbuster - for ... Chugai has commercialisation
-
Roche delivers solid sales gain in 2012
Perjeta has been tipped as a future blockbuster, as has Herceptin follow-up trastuzumab emtansine ( T-DM1), which is filed in the US and Europe and expected to be on the
-
Genentech cancer drug delayed
Genentech is seeking approval for trastuzumab-DM1 (T-DM1) for use in patients with advanced HER2-positive breast cancer who have previously received multiple HER2-targeted medicines and chemotherapies. ... T-DM1 links ImmunoGen's tumour-activated prodrug
More from news
Approximately 2 fully matching, plus 6 partially matching documents found.
Latest Intelligence
-
An eye towards the biobetter in South Korea
It was noteworthy that the Celltrion's announcement happened to coincide with Roche's clinical data presentation of its Herceptin biobetter, Trastuzumab-emtansine (T-DM1).
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Roche names John Reed as new head of early research
investigational medicines, such as breast cancer drug T-DM1.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Editorial Team Leader, Medical Communications, Oxford
-
Competitive Salary
- Graduate Business Analyst, Healthcare Communications – Pharma/ S...
-
Highly competitive salary
-
Head of Copy
-
£ competitive
- AstraZeneca’s Imfinzi and tremelimumab show unprecedented survival rate in liver cancer patients
- Sanofi and Regeneron’s Dupixent receives second positive phase 3 trial results
- Why pharma must get smart in its approach to customer engagement
- AstraZeneca's Enhertu receives FDA grant for priority review
- Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment
- Pfizer’s Cibinqo granted FDA approval for adults with moderate-to-severe atopic dermatitis
- Gilead’s Veklury receives FDA approval for non-hospitalised high-risk patients to treat COVID-19
- SMC approves Parkinson’s disease treatment Ongentys
- Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
- Home or away: where next for pharmaceutical symposia?
- PM announces plans to lift England’s COVID-19 restrictions
- Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment
- Why pharma must get smart in its approach to customer engagement
- AstraZeneca's Enhertu receives FDA grant for priority review
- Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb
- European biotech: a new generation of leaders emerges
- A rough guide to... advisory boards
- Country report: The healthcare market in Brazil
PMHub
TRIDUCIVE
Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...
Latest intelligence
- Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
- With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
- Cervical Cancer Prevention Month
- In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
- 6 critical success factors for flawless execution of a rapid first commercial launch
- Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....
